Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn’s Disease
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn’s Disease ; volume:68 ; number:6 ; day:15 ; month:3 ; year:2023 ; pages:2647-2657 ; date:6.2023
Digestive diseases and sciences ; 68, Heft 6 (15.3.2023), 2647-2657, 6.2023
- Creator
-
Straatmijer, Tessa
Biemans, Vince B. C.
Moes, Dirk Jan A. R.
Hoentjen, Frank
Heine, Rob ter
Maljaars, P. W. Jeroen
Theeuwen, Rosaline
Pierik, Marieke
Duijvestein, Marjolijn
Meulen-de Jong, Andrea E. van der
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10620-023-07822-7
- URN
-
urn:nbn:de:101:1-2023090813082531630113
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:00 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Straatmijer, Tessa
- Biemans, Vince B. C.
- Moes, Dirk Jan A. R.
- Hoentjen, Frank
- Heine, Rob ter
- Maljaars, P. W. Jeroen
- Theeuwen, Rosaline
- Pierik, Marieke
- Duijvestein, Marjolijn
- Meulen-de Jong, Andrea E. van der
- SpringerLink (Online service)
Other Objects (12)
Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn’s disease
Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn’s disease: a Chinese real-world study
Successful Drug Desensitization to Ustekinumab in a Patient with Crohn’s Disease
Ustekinumab inhibits T follicular helper cell differentiation in patients with Crohn’s disease
Posterior Reversible Encephalopathy Syndrome following Ustekinumab Induction for Crohn’s Disease
Elderly-onset Crohn’s disease remarkably responsive to ustekinumab: a case report
The Efficacy of Combination Therapy with Ustekinumab and Budesonide for Crohn’s Disease: A Randomized Controlled Trial
Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden
Comparison of surgery rates in biologic-naïve patients with Crohn’s disease treated with vedolizumab or ustekinumab: findings from SOJOURN
Pustular Rash in Crohn’s Patient on Ustekinumab Raises Concern for Drug-Induced Paradoxical Psoriasis
Cost-Effectiveness Analysis of Crohn’s Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist
Efficacy, drug sustainability, and safety of ustekinumab treatment in Crohn’s disease patients over three years
Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn’s disease
Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn’s disease: a Chinese real-world study
Successful Drug Desensitization to Ustekinumab in a Patient with Crohn’s Disease
Ustekinumab inhibits T follicular helper cell differentiation in patients with Crohn’s disease
Posterior Reversible Encephalopathy Syndrome following Ustekinumab Induction for Crohn’s Disease
Elderly-onset Crohn’s disease remarkably responsive to ustekinumab: a case report
The Efficacy of Combination Therapy with Ustekinumab and Budesonide for Crohn’s Disease: A Randomized Controlled Trial
Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden
Comparison of surgery rates in biologic-naïve patients with Crohn’s disease treated with vedolizumab or ustekinumab: findings from SOJOURN
Pustular Rash in Crohn’s Patient on Ustekinumab Raises Concern for Drug-Induced Paradoxical Psoriasis
Cost-Effectiveness Analysis of Crohn’s Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist
Efficacy, drug sustainability, and safety of ustekinumab treatment in Crohn’s disease patients over three years
Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn’s disease
Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn’s disease: a Chinese real-world study
Successful Drug Desensitization to Ustekinumab in a Patient with Crohn’s Disease
Ustekinumab inhibits T follicular helper cell differentiation in patients with Crohn’s disease
Posterior Reversible Encephalopathy Syndrome following Ustekinumab Induction for Crohn’s Disease
Elderly-onset Crohn’s disease remarkably responsive to ustekinumab: a case report
The Efficacy of Combination Therapy with Ustekinumab and Budesonide for Crohn’s Disease: A Randomized Controlled Trial
Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden
Comparison of surgery rates in biologic-naïve patients with Crohn’s disease treated with vedolizumab or ustekinumab: findings from SOJOURN
Pustular Rash in Crohn’s Patient on Ustekinumab Raises Concern for Drug-Induced Paradoxical Psoriasis
Cost-Effectiveness Analysis of Crohn’s Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist